Fcε<scp>RI</scp> expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy

Berings, Margot; Gevaert, Philippe; Ruyck, Natalie De; Derycke, Lara; Holtappels, Gabriële; Pilette, Charles; Bachert, Claus; Lambrecht, Bart N.; Dullaers, Mélissa

doi:10.1111/cea.13157

Cited by 32 publications

(24 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of high-affinity receptors can be elevated in response to increasing serum IgE. Irrespective of allergic status, IgE primarily binds to basophil rather than DC receptors [45]. Just recently, it was demonstrated that upon allergen exposure, increases in serum IgE are accompanied by expansion of IgE + plasmablasts.…”

Section: Early Phase Responsesmentioning

confidence: 99%

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Drazdauskaité

Layhadi

Shamji

2020

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review Allergic rhinitis (AR) is a chronic inflammatory immunoglobulin (Ig) E-mediated disease of the nasal mucosa that can be triggered by the inhalation of seasonal or perennial allergens. Typical symptoms include sneezing, rhinorrhea, nasal itching, nasal congestion and symptoms of allergic conjunctivitis. AR affects a quarter of the population in the United States of America and Europe. Recent Findings AR has been shown to reduce work productivity in 36–59% of the patients with 20% reporting deteriorated job attendance. Moreover, 42% of children with AR report reduced at-school productivity and lower grades. Most importantly, AR impacts the patient’s quality of life, due to sleep deprivation. However, a proportion of patients fails to respond to conventional medication and opts for the allergen immunotherapy (AIT), which currently is the only disease-modifying therapeutic option. AIT can be administered by either subcutaneous (SCIT) or sublingual (SLIT) route. Both routes of administration are safe, effective, and can lead to tolerance lasting years after treatment cessation. Both innate and adaptive immune responses that contribute to allergic inflammation are suppressed by AIT. Innate responses are ameliorated by reducing local mast cell, basophil, eosinophil, and circulating group 2 innate lymphoid cell frequencies which is accompanied by decreased basophil sensitivity. Induction of allergen-specific blocking antibodies, immunosuppressive cytokines, and regulatory T and B cell phenotypes are key pro-tolerogenic adaptive immune responses. Conclusion A comprehensive understanding of these mechanisms is necessary for optimal selection of AIT-responsive patients and monitoring treatment efficacy. Moreover, it could inspire novel and more efficient AIT approaches.

show abstract

Section: Early Phase Responsesmentioning

confidence: 99%

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Drazdauskaité

Layhadi

Shamji

2020

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

show abstract

“…Further, it's the degranulation of mast cells and basophils that leads to allergic inflammation and symptoms, like nasal congestion, itchy nose and ocular pruritus directly, but activity of mast cells and basophils is influenced by many factors besides activated T cells. It was found that serum sIgE/tIgE ratio may determine the density of FcɛRI-bound allergen sIgE and therefore the likelihood of allergens to cross-link FcɛRI and to induce basophil activation in allergic subjects [33]. MCs activation are mainly mediated by cross-linking of allergen-sIgE complexes and FcεRI receptors on the membrane surface of MCs [34], in some cases allergen specific IgGs can crosslink FcεRI bound allergen-IgE complexes and aggravate allergic inflammation [30].…”

Section: Discussionmentioning

confidence: 99%

Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study

Wang

Yin

Wang

et al. 2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background: Biomarkers of clinical efficacy for subcutaneous immunotherapy (SCIT) on allergic rhinitis (AR) have not been identified yet. This study aims to assess the clinical relevance of serum inhibitory activity for IgE by the method of enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) during SCIT for Artemisia-sensitized AR patients. Methods: 19 AR patients were studied who had undergone Artemisia-specific SCIT for more than 8 months (19.68 months on average, ranging from 9 to 33 months). Peripheral bloods were collected before and after treatment. The serum inhibitory activity for IgE was tested by ELIFAB and the level of Artemisia-specific IgG4 (Artemisia-sIgG4) was determined by ELISA. Clinical improvement was evaluated based on the symptom scores and rescue medication use (SMS). The 2-tailed Wilcoxon signed-rank test and the Spearman rank test (two-tailed) were used to analyze data by using SPSS 20.0, with P values of less than 0.05 considered as significant. Results: The SMS decreased significantly after SCIT (before: 12.79 ± 4.250, after: 6.11 ± 3.828, P = 0.000 < 0.01), the treatment was remarkably effective for 6 patients, effective for 10 and ineffective for 3, along with a total effective rate 84.21%. The serum inhibitory activity for IgE increased significantly after SCIT (P < 0.05) and was correlated with the levels of Artemisia-sIgG4 (r = − 0.501, P = 0.002 < 0.01). The levels of Artemisia-sIgG4 elevated dramatically after treatment (P < 0.01) and were related with the duration of treatment (r = 0.558, P = 0.000 < 0.01). But there was no relationship between clinical improvements and the serum inhibitory activity for IgE. Conclusions: The serum inhibitory activity for IgE increased significantly after SCIT, however, there was no correlation between it and clinical improvements by statistics analysis. So whether the serum inhibitory activity for IgE can act as biomarker of efficacy for SCIT or not needs to be studied further.

show abstract

“…Using this approach, we identified FcεRIα expression on pDCs, monocytes, cDCs and basophils ( Figure 1D), as previously demonstrated. 23 To investigate the association between atopy and asthma with performed as a way of interrogating trends observed within each individual cohort. Once combined, we observed an increased proportion of FcεRIα + pDCs in atopic/asthmatics compared to atopic/ non-asthmatics ( Figure 2C) and we also observed significantly greater FcεRIα expression levels on FcεRIα + pDCs, cDCs and basophils in atopic individuals (non-asthmatic and asthmatic) compared to non-atopic/non-asthmatics ( Figure 2D).…”

Section: Re Sultsmentioning

confidence: 99%

Progressive increase of FcεRI expression across several PBMC subsets is associated with atopy and atopic asthma within school‐aged children

Leffler

Read

Jones

et al. 2019

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Background Antigen‐specific IgE binds the Fcε receptor I (FcεRI) expressed on several types of immune cells, including dendritic cells (DCs). Activation of FcεRI on DCs in atopics has been shown to modulate immune responses that potentially contribute to asthma development. However, the extent to which DC subsets differ in FcεRI expression between atopic children with or without asthma is currently not clear. This study aimed to analyse the expression of FcεRI on peripheral blood mononuclear cells (PBMCs) from atopic children with and without asthma, and non‐atopic/non‐asthmatic age‐matched healthy controls. Methods We performed multiparameter flow cytometry on PBMC from 391 children across three community cohorts and one clinical cohort based in Western Australia. Results We confirmed expression of FcεRI on basophils, monocytes, plasmacytoid and conventional DCs, with higher proportions of all cell populations expressing FcεRI in atopic compared to non‐atopic children. Further, we observed that levels of FcεRI expression were elevated across plasmacytoid and conventional DC as well as basophils in atopic asthmatic compared to atopic non‐asthmatic children also after adjusting for serum IgE levels. Conclusion Our data suggest that the expression pattern of FcεRI on DC and basophils differentiates asthmatic from non‐asthmatic atopic children. Given the significant immune modulatory effects observed as a consequence of FcεRI expression, this altered expression pattern is likely to contribute to asthma pathology in children.

show abstract

FcεRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy

Cited by 32 publications

References 64 publications

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study

Progressive increase of FcεRI expression across several PBMC subsets is associated with atopy and atopic asthma within school‐aged children

Contact Info

Product

Resources

About